Published in J Clin Invest on July 25, 2016
Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation. Arthritis Rheumatol (2017) 0.77
The effects of pravastatin on the normal human placenta: Lessons from ex-vivo models. PLoS One (2017) 0.75
Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome. J Clin Invest (2016) 0.75
The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet (2017) 0.75
Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function. Comput Struct Biotechnol J (2017) 0.75
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis. Lancet (2011) 8.28
Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol (2013) 6.24
Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ (2005) 5.96
Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol (2009) 2.58
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
New doppler technique for assessing uteroplacental blood flow. Lancet (1983) 2.15
Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med (2004) 1.95
Statins and congenital malformations: cohort study. BMJ (2015) 1.75
Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol (1999) 1.74
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A (2010) 1.56
Maternal complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG (2014) 1.54
Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost (2014) 1.46
Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol (2010) 1.26
Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest (2008) 1.23
Role of complement component C1q in the onset of preeclampsia in mice. Hypertension (2011) 1.22
A new mouse model to explore therapies for preeclampsia. PLoS One (2010) 1.21
Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol (1992) 1.21
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis (2014) 1.11
Learning from the placenta: acute atherosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health. Hypertension (2010) 1.11
Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood (2013) 1.10
First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn (2010) 1.04
Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol (2014) 0.96
Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. Hypertension (2015) 0.93
The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta (2005) 0.93
Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol (2013) 0.89
Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol (2015) 0.88
Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med (2015) 0.85
Management of preeclampsia. Pregnancy Hypertens (2014) 0.84
Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost (2011) 0.83
Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol (2009) 0.83
Hypertension during pregnancy, with and without specific hypotensive treatment. I. Perinatal factors and neonatal morbidity. Early Hum Dev (1977) 0.83
Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol (2008) 0.83
A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis (2013) 0.82
Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth (2009) 0.82
Long-term maternal morbidity and mortality associated with ischemic placental disease. Semin Perinatol (2014) 0.81
Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth. Semin Thromb Hemost (1999) 0.81
Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension (2014) 0.80
Antiphospohlipid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol (2011) 0.80
Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol (1996) 0.80
Placental pathology in antiphospholipid syndrome. Lupus (1998) 0.80
Can statins prevent pregnancy complications? J Reprod Immunol (2013) 0.79
Bed rest in pregnancy. Mt Sinai J Med (2011) 0.78
Immunotherapy in antiphospholipid syndrome. Int Immunopharmacol (2015) 0.77
Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet (2012) 2.83
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med (2002) 2.09
Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest (2010) 1.77
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol (2005) 1.67
Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod (2003) 1.65
Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem (2005) 1.62
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood (2007) 1.49
Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod (2005) 1.43
Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum (2005) 1.26
Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice. Am J Pathol (2011) 1.25
Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest (2008) 1.23
TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol (2005) 1.23
Role of complement component C1q in the onset of preeclampsia in mice. Hypertension (2011) 1.22
A new mouse model to explore therapies for preeclampsia. PLoS One (2010) 1.21
Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol (2004) 1.20
Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn (2011) 1.08
Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci U S A (2006) 1.08
Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood (2009) 1.02
Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood (2009) 1.01
Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. J Neurosci (2006) 0.99
An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol (2010) 0.98
Cervical remodeling/ripening at term and preterm delivery: the same mechanism initiated by different mediators and different effector cells. PLoS One (2011) 0.97
The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol (2007) 0.97
Female fertility and colorectal cancer. Int J Colorectal Dis (2008) 0.97
Acute pancreatitis in pregnancy: an overview. Eur J Obstet Gynecol Reprod Biol (2011) 0.97
Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol (2011) 0.96
The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun (2004) 0.94
Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth. Biochim Biophys Acta (2013) 0.93
Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol (2007) 0.93
Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril (2004) 0.92
Creatine phosphokinase in ectopic pregnancy revisited: significant diagnostic value of its MB and MM isoenzyme fractions. Am J Obstet Gynecol (2006) 0.89
Frontomaxillary facial angle in fetuses with trisomy 21 at 11-13(6) weeks. Am J Obstet Gynecol (2007) 0.89
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril (2007) 0.89
Receiver operator characteristics and diagnostic value of progesterone and CA-125 in the prediction of ectopic and abortive intrauterine gestations. Eur J Obstet Gynecol Reprod Biol (2005) 0.87
Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol (2008) 0.87
The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones (Athens) (2011) 0.86
Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation. Trans Am Clin Climatol Assoc (2007) 0.86
Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci (2005) 0.86
Nandrolone abuse decreases anxiety and impairs memory in rats via central androgenic receptors. Int J Neuropsychopharmacol (2008) 0.86
GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol (2012) 0.85
Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy. Int J Neuropsychopharmacol (2007) 0.85
Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine (2013) 0.85
Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med (2008) 0.85
Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med (2007) 0.84
Mature ovarian teratoma with carcinoid tumor in a 28-year-old patient. Case Rep Obstet Gynecol (2013) 0.84
Evaluation of serum tumour markers concentrations in patients with homozygous beta-thalassaemia in relation to demographical, clinical and biochemical parameters. Ann Hematol (2007) 0.84
Immigrants present improved obstetric and neonatal outcomes compared to native women. A northern greek population analysis. J Immigr Minor Health (2013) 0.84
Serum luteinizing hormone levels are markedly increased and significantly correlated with Delta 4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril (2005) 0.84
Round-headed spermatozoa in semen specimens from fertile and subfertile men. J Reprod Med (2002) 0.84
Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol (2006) 0.83
Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome. Fertil Steril (2006) 0.83
Primary mesenteric smooth muscle tumor: an entity with unpredictable biologic behavior. Case Rep Obstet Gynecol (2013) 0.83
Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases. Gynecol Endocrinol (2005) 0.83
High efficiency near diffraction-limited mid-infrared flat lenses based on metasurface reflectarrays. Opt Express (2016) 0.82
Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test. Fertil Steril (2005) 0.81
Complex Rearrangement Involving Three Chromosomes, Four Breakpoints and a 2.7-Mb Deletion in the 18q Segment Observed in a Girl with Mild Learning Difficulties. Cytogenet Genome Res (2015) 0.81
Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension (2014) 0.80
Parameters affecting latency period in PPROM cases: a 10-year experience of a single institution. J Matern Fetal Neonatal Med (2013) 0.79
Comparison of the mechanisms responsible for cervical remodeling in preterm and term labor. J Reprod Immunol (2013) 0.79
Operator experience reduces the risk of second trimester amniocentesis-related adverse outcomes. Eur J Obstet Gynecol Reprod Biol (2013) 0.79
Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC Cancer (2014) 0.79
Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol (2012) 0.79
Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. Cytokine (2012) 0.79
Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol (2006) 0.78
The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. Eur J Endocrinol (2013) 0.78
Multifollicular ovaries in female adolescents with cystic fibrosis. Fertil Steril (2006) 0.78
Aneurysm of the vein of galen diagnosed with MRI. Case Rep Obstet Gynecol (2013) 0.77
Resistin as a local factor in polycystic ovary syndrome: a novel view of "adipo(cyto)kines"? Hum Reprod (2004) 0.77
Endometrial adenocarcinoma and mucocele of the appendix: an unusual coexistence. Case Rep Obstet Gynecol (2013) 0.77
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecol Endocrinol (2011) 0.77
Placental volume at 11-13 weeks' gestation in the prediction of birth weight percentile. Fetal Diagn Ther (2011) 0.76
The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. Blood Coagul Fibrinolysis (2009) 0.76
Common features and differences of the hypothalamic-pituitary-gonadal axis in male and female. Gynecol Endocrinol (2014) 0.76
Fertility preservation for young women with rectal cancer--a combined approach from one referral center. J Gastrointest Surg (2010) 0.75
Response to: Media effect-letter to the editor about the manuscript titled Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet (2014) 0.75
Level of knowledge about genital chlamydial infection among Greek midwives and midwifery students. Scand J Infect Dis (2010) 0.75
Do characteristic spermatozoal morphological abnormalities exist in patients who have undergone unilateral orchiectomy and preventive radiotherapy? Int J Fertil Womens Med (2003) 0.75
Cumulative High-Grade Squamous Intraepithelial Lesion Rate and Need for Surgical Intervention of Atypical Squamous Cells of Undetermined Significance Cytology-Diagnosed Patients: A Prospective Study. Gynecol Obstet Invest (2016) 0.75
Amniocentesis-related adverse outcomes in diamniotic twins: is there a difference compared to singleton pregnancies? Eur J Obstet Gynecol Reprod Biol (2010) 0.75
Current contraceptive awareness and use in Greek dental school students. J Womens Health (Larchmt) (2009) 0.75
Case of prenatally diagnosed non-mosaic trisomy 20 with minor abnormalities. J Obstet Gynaecol Res (2010) 0.75
Deletion of 4.4 Mb at 2q33.2q33.3 May Cause Growth Deficiency in a Patient with Mental Retardation, Facial Dysmorphic Features and Speech Delay. Cytogenet Genome Res (2015) 0.75
The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. Fertil Steril (2007) 0.75
Rapid detection of D-Dimers with mLabs® whole blood method for venous thromboembolism exclusion. Comparison with Vidas® D-Dimers assay. Int Angiol (2015) 0.75
Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency. Int J Hematol (2007) 0.75
Successful pregnancy and delivery in a young woman with cystic fibrosis and gestational diabetes. J Cyst Fibros (2002) 0.75